Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for N-acetylcysteine  COVID-19 treatment studies for N-acetylcys..  C19 studies: N-acetylcys..  N-acetylcys..   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Case 26% Improvement Relative Risk c19early.org/na Huh et al. N-acetylcysteine for COVID-19 Prophylaxis Does N-acetylcysteine reduce COVID-19 infections? Retrospective 65,149 patients in South Korea Fewer cases with N-acetylcysteine (p<0.000001) Huh et al., medRxiv, doi:10.1101/2020.05.04.20089904 Favors N-acetylcysteine Favors control
Association of previous medications with the risk of COVID-19: a nationwide claims-based study from South Korea
Huh et al., medRxiv, doi:10.1101/2020.05.04.20089904 (Preprint)
Huh et al., Association of previous medications with the risk of COVID-19: a nationwide claims-based study from South.., medRxiv, doi:10.1101/2020.05.04.20089904 (Preprint)
May 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective database analysis of 65,149 in South Korea, showing significantly lower cases with existing N-acetylcysteine treatment. The journal version of this paper does not present the N-acetylcysteine results.
risk of case, 26.2% lower, RR 0.74, p < 0.001, treatment 710 of 13,788 (5.1%), control 4,462 of 51,361 (8.7%), adjusted per study, odds ratio converted to relative risk, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Huh et al., 4 May 2020, retrospective, database analysis, South Korea, preprint, 10 authors.
Contact: eastside1st@gmail.com.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperN-acetylcys..All
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.05.04.20089904; this version posted May 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Association of previous medications with the risk of COVID-19: a nationwide claimsbased study from South Korea Running title: Use of previous medications and COVID-19 in Korea Kyungmin Huh1¶, Wonjun Ji2¶, Minsun Kang3¶, Jinwook Hong3, Gi Hwan Bae3, Rugyeom Lee3, Yewon Na3, Hyoseon Choi4, Seon Yeong Gong4, Jaehun Jung3, 4* 1 Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea 2 Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea 3 Artificial Intelligence and Big-Data Convergence Center, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea 4 Department of Preventive Medicine, Gachon University College of Medicine, Incheon, Korea ¶ KH, WJ, and MK contributed equally to this work. Keywords: COVID-19, drug repositioning, treatment, prophylaxis Running title: Use of various medications and COVID-19 Word count: 2,729 * Corresponding author: 1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.05.04.20089904; this version posted May 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Jaehun Jung, MD, PhD Department of Preventive Medicine, Gachon University College of Medicine 38-13, Dokjeom-ro 3, Incheon, Korea E-mail: eastside1st@gmail.com Abbreviations: ACE2, angiotensin-converting enzyme 2; ACEIs, ACE inhibitors; aOR, adjusted odds ratio; ARBs, angiotensin receptor blockers; CCI, Charlson comorbidity index; CI, confidence interval; COVID-19, coronavirus disease; CQ, chloroquine; HCQ, hydroxychloroquine; HIRA, Health Insurance Review & Assessment Service; ICD-10, International Classification of Diseases and Related Health Problems, 10th edition; OR, odds ratio; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. 2 medRxiv preprint doi: https://doi.org/10.1101/2020.05.04.20089904; this version posted May 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Abstract Background. Identifying the association between medications taken prior to the infection of coronavirus disease (COVID-19) might be useful during the current pandemic until a proven treatment is developed. We aimed to determine whether the risk of developing COVID-19 was associated with the use of various drugs that may increase or decrease susceptibility to severe acute respiratory syndrome coronavirus 2 infection and COVID-19. Methods and Findings: A case-control study was performed using a nationwide claims database of South Korea, where a large testing capacity has been available throughout..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit